Oncorus Balans Gezondheid

Financiële gezondheid criteriumcontroles 2/6

Oncorus heeft een totaal eigen vermogen van $31.1M en een totale schuld van $20.5M, wat de schuld-eigenvermogensverhouding op 66% brengt. De totale activa en totale passiva bedragen respectievelijk $109.8M en $78.6M.

Belangrijke informatie

66.0%

Verhouding schuld/eigen vermogen

US$20.54m

Schuld

Rente dekkingsratio	n/a
Contant	US$44.98m
Aandelen	US$31.12m
Totaal verplichtingen	US$78.63m
Totaal activa	US$109.75m

Recente financiële gezondheidsupdates

We're Not Very Worried About Oncorus' (NASDAQ:ONCR) Cash Burn Rate

Oct 14

Recent updates

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( $46.7M ) ONCR } overtreffen de korte termijn passiva ( $31.1M ).

Langlopende schulden: De kortetermijnactiva van ONCR ( $46.7M ) dekken de langetermijnschulden ( $47.5M ) niet.

Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: ONCR heeft meer geld in kas dan de totale schuld.

Schuld verminderen: De schuld/eigen vermogen-ratio van ONCR is de afgelopen 5 jaar gestegen van 0% naar 66%.

Balans

Analyse van de cashflow

Voor bedrijven die in het verleden gemiddeld verliesgevend zijn geweest, beoordelen we of ze ten minste 1 jaar kasstroom hebben.

Stabiele cash runway: Er zijn onvoldoende gegevens om te bepalen of ONCR voldoende cash runway heeft op basis van de huidige vrije kasstroom.

Voorspelling contante baan: Er zijn onvoldoende gegevens om te bepalen of ONCR voldoende cash runway heeft als de vrije kasstroom blijft groeien of krimpen op basis van historische percentages.

Oncorus Balans Gezondheid

Financiële gezondheid criteriumcontroles 2/6

Belangrijke informatie

Recente financiële gezondheidsupdates

Oncorus, Inc. Files Form 15

Nasdaq to Delist the Common Stock of Oncorus

Oncorus Receives Written Notice from The Nasdaq Stock Market LLC Regarding in Light of the Plan of Dissolution

Oncorus, Inc. announced delayed 10-Q filing

Nasdaq Grants Oncorus an Additional 180 Calendar Days, or Until October 30, 2023, to Regain Compliance with the Minimum Closing Bid Price

We're Not Very Worried About Oncorus' (NASDAQ:ONCR) Cash Burn Rate

Recent updates

Oncorus, Inc. Files Form 15

Nasdaq to Delist the Common Stock of Oncorus

Oncorus, Inc.(OTCPK:ONCR) dropped from S&P TMI Index

Oncorus Receives Written Notice from The Nasdaq Stock Market LLC Regarding in Light of the Plan of Dissolution

Oncorus Announces Management Changes

Oncorus, Inc. Announces Workforce Reduction Plan

Oncorus, Inc. Appoints Alexander Nolte as Principal Accounting Officer

Oncorus, Inc. announced delayed 10-Q filing

Nasdaq Grants Oncorus an Additional 180 Calendar Days, or Until October 30, 2023, to Regain Compliance with the Minimum Closing Bid Price

Oncorus, Inc. Announces Portfolio Reprioritization to Focus on IV-Administered, Self-Amplifying RNA Medicines for Patients with Cancer

Oncorus, Inc. Announces the Presentation of Preclinical Data for ONCR-719 in A Poster At the 2022 Society for Neuro-Oncology Annual Meeting

Price target decreased to US$5.75

Oncorus Announces Publication in Nature Communications Highlighting the Development of its Intravenously Administered Synthetic vRNA/LNP Platform for the Treatment of Cancer

Now 23% undervalued

Oncorus GAAP EPS of -$0.74 misses by $0.02

Oncorus, Inc. Appoints Douglas Fambrough to Board of Directors

Oncorus, Inc., Annual General Meeting, Jun 22, 2022

Oncorus, Inc. Announces the Appointment of Richard Wanstall as Chief Financial Officer

Price target decreased to US$17.00

Oncorus, Inc. Presents Preclinical Data on ONCR-021 and ONCR-788 Supporting Selectively Self-Amplifying vRNA Immunotherapy Platform at AACR Annual Meeting

Oncorus, Inc. announced that it expects to receive $45 million in funding from K2 HealthVentures

Oncorus, Inc. Promotes John Goldberg to Chief Medical Officer

President exercised options to buy US$184k worth of stock.

COO & Chief of Staff recently bought US$174k worth of stock

Price target decreased to US$34.75

President exercised options to buy US$469k worth of stock.

We're Not Very Worried About Oncorus' (NASDAQ:ONCR) Cash Burn Rate

Oncorus: Shares Look Cheap As First Oncolytic Viral Therapy Enters Clinic

Oncorus, Inc.(NasdaqGM:ONCR) dropped from Russell 3000E Growth Index

Independent Director Robert Kirkman has left the company

Independent Director Cameron Wheeler has left the company

Oncorus Announces Nomination of its First IV-Administered Synthetic Viral RNA (vRNA) Immunotherapy Product Candidates, ONCR-021 and ONCR-788

Insider exercised options to buy US$590k worth of stock.

Oncorus (NASDAQ:ONCR) Is In A Good Position To Deliver On Growth Plans

Independent Director has left the company

Oncorus Anticipates Reporting Interim Data from its Ongoing Phase 1 Clinical Trial of its Lead oHSV-Based Clinical Candidate ONCR-177 in Patients with Solid Tumor Indications in the Second Half of 2021

What Kind Of Shareholders Own Oncorus, Inc. (NASDAQ:ONCR)?

New 90-day low: US$20.97

Oncorus: Buy On A Dip, Potential Already Priced In At Current Levels

Oncorus, Inc. Announces Publication of Preclinical Data Demonstrating Potent Systemic Antitumor Activity of its Clinical Stage Oncolytic Herpes Simplex Viral Immunotherapy Product Candidate ONCR-177

New 90-day high: US$35.55

Oncorus to build viral immunotherapy clinical manufacturing facility in U.S.

We're Not Very Worried About Oncorus' (NASDAQ:ONCR) Cash Burn Rate

Oncorus Appoints Scott Canute to Its Board of Directors

Oncorus reports Q3 results

Oncorus, Inc. has filed an IPO in the amount of $86.25 million.

Analyse van de financiële positie

Schuld/ eigen vermogen geschiedenis en analyse

Balans

Analyse van de cashflow

Ontdek gezonde bedrijven